Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
Lokahi Therapeutics, a subsidiary of Glucotrack (Nasdaq: GCTK), will continue its ai2 Pipeline collaboration with The University of Alabama's Culverhouse College of Business for the upcoming academic year. In its first year, the ai2 Futures Lab engaged 64 students and identified more than 45 potential therapeutic assets, several of which advanced into active pipeline discussions. Student teams work alongside industry professionals on market analysis, intellectual property assessment, regulatory strategy, and commercialization planning, with recommendations that may inform licensing or acquisition decisions.
Key figures
- Program
- ai2 Futures Lab first year
- Potential assets identified
- 45+
- Students engaged first year
- 64
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.